San Yan Bio secures first RMB 10 million+ round to advance AI-powered synthetic biology for high-end medical aesthetic ingredients and ECM industrialization

Recently, San Yan Bio announced the completion of its first financing round of over RMB 10 million. This round was led by Jianchuang Medical Growth Fund. The proceeds will be primarily used for the expansion of high-level production capacity of core functional ingredients, including recombinant humanized protein series and ultra-small molecule sodium hyaluronate, at the company's core subsidiary, Sansheng Meijian; the deep upgrade of its AI-driven synthetic biology technology platform; and the accelerated research and development and regulatory filing of multiple medical aesthetics pipeline products in the extracellular matrix (ECM) field.

This financing round marks San Yan Bio's first introduction of external institutional investors, fully reflecting leading capital's strong interest in the intersection of artificial intelligence and synthetic biology, the internationalization of high-end medical aesthetic ingredients, and the emerging ECM skincare area. It also demonstrates firm confidence in the technical strength, industrialization capability, and sustained leadership of the San Yan Bio team in driving progress within the ECM industry.

As a biotechnology company leading the new era of ECM skincare, Sansheng Meijian, the core subsidiary of San Yan Bio, is committed to efficiently integrating artificial intelligence with synthetic biology to build an internationally leading platform for extracellular matrix (ECM) functional ingredients. Leveraging its proprietary high-level expression system and AI-assisted protein design platform, the company has successfully achieved high-level expression and industrial application of multiple core functional ingredients, including recombinant humanized elastin, recombinant humanized fibronectin, recombinant humanized copper-zinc superoxide dismutase (Cu/Zn-SOD), and ultra-small molecule sodium hyaluronate. While retaining natural biological activity, these products have achieved large-scale production with high purity and high batch-to-batch consistency, demonstrating significant advantages in anti-aging and repair, tissue regeneration, deep hydration, and antioxidation, with outstanding technical and application benefits.

Guided by its mission to "reconstruct the beauty of skin with technology," Sansheng Meijian is driving the integration of artificial intelligence into the field of synthetic biology with greater intensity. The company will continue its deep cultivation in the extracellular matrix (ECM) field, constantly deepening its deployment and development of ECM-related medical aesthetics pipelines. It has established a complete platform encompassing AI-assisted enzyme design, high-throughput screening, fermentation and purification process development, as well as a full-chain research and development system covering raw materials, formulations, and end products.

Looking to the future, San Yan Bio and Sansheng Meijian will further accelerate the continuous development of ECM applications in the medical aesthetics field, promoting the rapid launch of pipelines including recombinant protein raw materials, ultra-small molecule sodium hyaluronate, active lyophilized powders, medical aesthetic repair dressings, and customized functional ingredient solutions. The company will remain committed to deep cultivation in the ECM field, continuously leading the technological progress and industrialization direction of the ECM industry, redefining the standards of skin health with technology, and serving every partner with dedication.

This financing round represents an important milestone in the development journey of San Yan Bio. Taking this opportunity, the company will continue to increase its investment in the AI synthetic biology platform, GMP-grade raw material production lines, and the ECM medical aesthetics product matrix, comprehensively enhancing its research and development capabilities and production capacity, and helping China's domestic high-end medical aesthetic raw materials reach global markets.